MC3343 (DC10940) chemical structure
Chemical structureResearch use only
CAT. NO. DC10940Featured

MC3343

Pack size & price

USD
Total$450
We match the best price and quality on market.
Product overview

Description & Application

MC3343 is a nonnucleoside DNMT inhibitor for epigenetic reprogramming, osteoblastic differentiation and osteosarcoma research.

ParameterValue
Chemical NameN-[3-[(2-Amino-6-methylpyrimidin-4-yl)amino]phenyl]-3-(quinolin-4-ylamino)benzamide
CAS No.1535187-91-7
SynonymsMC3343; BDBM50448484; N-(3-((2-Amino-6-methylpyrimidin-4-yl)amino)phenyl)-3-(quinolin-4-ylamino)benzamide; N-(3-(2-amino-6-methylpyrimidin-4-ylamino)phenyl)-3-(quinolin-4-ylamino)benzamide; N-[3-[(2-Amino-6-methylpyrimidin-4-yl)amino]phenyl]-3-(quinolin-4-ylamino)benzamide
FormulaC27H23N7O
M.Wt461.5178
SMILESO=C(C1C([H])=C([H])C([H])=C(C=1[H])N([H])C1=C([H])C([H])=NC2=C([H])C([H])=C([H])C([H])=C12)N([H])C1=C([H])C([H])=C([H])C(=C1[H])N([H])C1C([H])=C(C([H])([H])[H])N=C(N([H])[H])N=1
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
DNA methyltransferases · Literature evidence

Biological Activity

MC3343 is a nonnucleoside DNMT inhibitor for epigenetic reprogramming, osteoblastic differentiation and osteosarcoma research. MC3343 arrested cells in G1 or G2/M and re-expressed genes associated with osteoblast differentiation.

In Vitro

EndpointModel / conditions / sourceReported result
Proliferation and differentiationHuman osteosarcoma models. [1]MC3343 arrested cells in G1 or G2/M and re-expressed genes associated with osteoblast differentiation.
Comparison with 5-azadCOsteosarcoma cells; DNMT-inhibitor comparison. [1]Antiproliferative effects were similar, but the differentiation response differed from the nucleoside inhibitor.
Chemotherapy combinationsMC3343 with doxorubicin or cisplatin. [1]Combination effects included increased stable doxorubicin–DNA association, sustained DNA damage and greater cell death.

In Vivo

EndpointModel / conditions / sourceReported result
Patient-derived modelOsteosarcoma PDX. [1]A mature osteoblast phenotype and sustained cytostatic response were reported in vivo. Exact exposure conditions are not available in the verified abstract.

Interpretation

Differentiation and cytotoxicity are separate outcomes; combination findings are not monotherapy response rates.

Original studies

Original study ↗

References

  1. Manara MC, et al. A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular cancer therapeutics (2018).

Product documentation

View COAView MSDSView online datasheet

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

For additional quantities or product documentation, contact info@dcchemicals.com.

Solution calculatorBrowse small molecules

Related research products

WM-1119 chemical structureDC10881

WM-1119

WM-1119 is a KAT6A/KAT6B inhibitor for epigenetic and cellular-senescence research. The primary study reports binding selectivity, lymphoma-cell growth inhibition and suppression of lymphoma progression in mice.

View activity & prices
WM-8014 chemical structureDC10880

WM-8014

WM-8014 is a KAT6A/KAT6B inhibitor for chromatin, cellular senescence and cancer research. Published work separates biochemical inhibition, fibroblast growth arrest and responses in a zebrafish liver cancer model.

View activity & prices
OTS193320 chemical structureDC11256

OTS193320

OTS193320 is a SUV39H2 methyltransferase inhibitor for histone methylation, DNA-damage-response and cancer-cell research.

View activity & prices

Cart

Request quotation